RMC-6291 is under clinical development by Revolution Medicines and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RMC-6291’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RMC-6291 is under development for the treatment of solid tumor, non-small cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma. The drug candidate is a second-generation, tri-complex inhibitors. It is administered through oral route. It acts by targeting the GTP bound form of KRAS (G12C) and NRAS (G12C).
Revolution Medicines overview
Revolution Medicines is a clinical-stage precision oncology company that discover and developed medicines and therapies for cancer patients. The company product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. Its other product includes RMC-4630, RMC-5552, SOS1. Revolution Medicines also provide a research and development pipeline comprising RAS(ON) inhibitors that bind directly to RAS variants. The company partners with pharmaceutical companies and healthcare organizations for its drug development activities. Revolution Medicines is headquartered in Redwood City, California, the US
For a complete picture of RMC-6291’s drug-specific PTSR and LoA scores, buy the report here.